Level C· Early human research exploring benefitsProspective StudyPubMed

Predictive Factors of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Therapy's Success in the Treatment of Perianal Fistulas in Patients With Crohn's Disease.

Oubaha S., Nacir O., Zouaki I., Krati K.

Prospective Study on Autoimmune Research, published in Cureus (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cureus (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40861684
DOI
10.7759/cureus.88534

Abstract (original English)

Introduction Crohn's disease (CD)-associated perianal fistulas are a challenging and debilitating complication, often resistant to standard medical and surgical treatments. Mesenchymal stem cell (MSC) therapy, particularly using adipose- or bone marrow-derived MSCs (AMSCs/BM-MSCs), offers a promising regenerative approach, yet data on autologous BM-MSCs remain limited. Objective This pilot study aimed to evaluate the safety and efficacy of autologous BM-MSCs in treating perianal fistulas in CD patients, and to identify potential predictive factors influencing treatment outcomes. Methods A single-center, prospective, single-blind randomized study was conducted over six months at Mohammed VI University Hospital in Marrakech, Morocco. Twenty CD patients with complex perianal fistulas unresponsive to conventional therapy were enrolled, of whom eight completed the 24-week follow-up. Patients were randomized into two groups: local BM-MSC administration only (CroMaPCs) and combined local plus intravenous administration (CroMaPCs+). Outcomes were assessed clinically and radiologically at Weeks 2, 6, and 24. Results At 24 weeks, complete fistula healing was observed in three patients (37.5%), with higher response and healing rates in the CroMaPCs+ group (50%) compared to the CroMaPCs group (25%). No treatment-related adverse events were reported. Factors such as age, immunosuppressive t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research